Wednesday, May 12, 2021
Thursday, May 6, 2021
Wednesday, April 28, 2021
Tuesday, April 27, 2021
Sunday, April 25, 2021
Saturday, April 24, 2021
Friday, April 23, 2021
Wednesday, April 21, 2021
Tuesday, April 20, 2021
Sunday, April 18, 2021
Saturday, April 17, 2021
Thursday, April 15, 2021
Tuesday, April 13, 2021
Sunday, April 11, 2021
Thursday, April 8, 2021
Public Health Director Barbara Ferrer noted that, due to the expense, "Very few of our specimens are genetically tested in this way." Statewide, only 5% of tests are run through genomic sequencing, according to California's top health officer. The rate is even less at the county level.
According to the other article I posted, the Pfizer vaccine is 2/3 less effective against the South African Variant and the Moderna Vaccine is 6.4 times less effective.
Sunday, April 4, 2021
You may be wondering if the coronavirus variants have an impact on the effectiveness of our current vaccines.
From what we know so far, it appears that the current vaccines may be less effective for B.1.351, the variant first identified in South Africa. This is currently an area of ongoing, intense research.
Let's look at a snapshot of what some of the data says so far.
Large-scale clinical trials of the Pfizer-BioNTech vaccine found a vaccine effectiveness of 95 percent against the original version of the new coronavirus.
This vaccine is currently authorized for emergency use in the United States.
A recent study investigated the effectiveness of this vaccine for test viruses containing the mutations found in B.1.351. To do this, serum from individuals who had been vaccinated with the Pfizer-BioNTech vaccine was used.
Researchers found that this serum, which contains antibodies, was less effective against B.1.351. In fact, neutralization of test viruses containing all of the mutations present in B.1.351 was reduced by two-thirds.
What about B.1.1.7, the variant first seen in the U.K.?
A study similar to the one we've discussed above found that neutralization of test viruses with the spike protein of B.1.1.7 was only slightly lower than it was for earlier versions of the coronavirus.
The large-scale clinical trials on the Moderna vaccine determined that vaccine effectiveness was 94.1 percent against the original version of the new coronavirus.
Like the Pfizer-BioNTech vaccine, the Moderna vaccine has been authorized for emergency use in the United States.
A recent study looked into the effectiveness of the Moderna vaccine for the B.1.1.7 and B.1.351 variants. In order to do this, researchers used serum from individuals who had received the Moderna vaccine and test viruses containing the spike proteins from the variants.
It was found that test viruses with the B.1.1.7 spike protein were neutralized in a similar manner to earlier versions of the coronavirus.
However, neutralization of test viruses with the spike protein of B.1.351 was 6.4-fold lower.
Johnson & Johnson vaccine
The Johnson & Johnson vaccine is the third COVID-19 vaccine to be authorized for emergency use in the United States.
Unlike the Pfizer-BioNTech and Moderna vaccines, it only requires one dose.
This vaccine has yet to be tested against specific variants. However, large-scale clinical trials were performed in places where variants are circulating, such as South Africa and South America.
According to the data released from clinical trialsTrusted Source, the effectiveness of this vaccine 28 days after vaccination is:
66 percent effective overall
72 percent in the United States
66 percent effective in South America, where the P.1 variant is circulating
57 percent effective in South Africa, where the B.1.351 variant is circulating
85 percent effective at preventing severe COVID-19 symptoms across all geographical regions
The U.S. added almost 65,000 new Covid-19 cases on Saturday and remains on pace for the most weekly infections since the end of February. North Dakota has gone nine days without a Covid-19 fatality, the longest stretch since the first death there.
Friday, March 26, 2021
Sunday, March 21, 2021
Johnson & Johnson Vaccine
Friday, March 19, 2021
Tuesday, March 16, 2021
Thursday, March 11, 2021
Monday, March 8, 2021
Monday, March 1, 2021
Saturday, February 27, 2021
Don't become one of these people, if you can help it.
Friday, February 19, 2021
Thursday, February 18, 2021
Sunday, February 14, 2021
Saturday, February 13, 2021
Friday, February 12, 2021
Wednesday, February 10, 2021
Saturday, February 6, 2021
Thursday, February 4, 2021
Wednesday, February 3, 2021
Monday, February 1, 2021
Monday, January 25, 2021
Saturday, January 23, 2021
Tuesday, January 12, 2021
Saturday, January 9, 2021
Thursday, January 7, 2021
mRNA Vaccines Might Prove Catastrophic in a Rushed Coronavirus Response
Bombshell primer breaks down the very real risks of this cutting-edge technology
The FDA says Pfizer’s Covid vaccine is safe and effective. But trial participants warn of intense symptoms after second shot
Others experienced headaches and fatigue.
The FDA said that while side effects of the Pfizer vaccine are common, there are "no specific safety concerns identified that would preclude issuance of an EUA."
From what I can tell by casual observation, maybe 10 to 20% of the population doesn't want to take the vaccine.
Ivermectin has antiviral effects against several distinct positive-sense single-strand RNA viruses, including SARS-CoV-2. On 10 April 2020, the FDA issued guidance to not use veterinary-grade ivermectin as treatment for COVID-19 in humans.
Ivermectin inhibits replication of SARS-CoV-2 in monkey kidney cell culture with an IC50 of 2.2 - 2.8 µM, making it a possible candidate for COVID-19 drug repurposing research. The doses used in cell culture would require 104 larger doses in humans based on this data, which does not look promising as an effective treatment for COVID-19. Such high doses of ivermectin are not covered by the current human-use approvals of the drug and could be dangerous, as the likely antiviral mechanism of action is the suppression of a host cellular process, specifically the inhibition of nuclear transport by importin α/β1.
A preprint published in April 2020 claimed benefits of ivermectin in the treatment of COVID-19, but it was a retrospective study based on questionable hospital data from Surgisphere and was withdrawn at the end of May. The preprint led to several government agencies in Latin America recommending ivermectin as a COVID-19 treatment; these recommendations were later denounced by the regional WHO office. On October 12, 2020 Peru withdrew its authorization to use ivermectin and hydroxychloroquine as COVID-19.